Recombinant Human LIGHT/CD258 protein (His Tag)

种属

Human

纯度

>95 %, SDS-PAGE

标签

His Tag

生物活性

EC50: 0.1-0.4 ng/mL

Cat no : Eg32095

Print datasheet

Synonyms

LIGHT, CD258, HVEM L, HVEML, HVEM-L



产品信息

纯度 >95 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性 Immobilized Human HVEM (Myc tag, His tag) at 2 μg/mL (100 μL/well) can bind Human LIGHT (His tag) with a linear range of 0.1-0.4 ng/mL.
来源 HEK293-derived Human LIGHT protein Asp74-Val240 (Accession# O43557) with a His tag at the N-terminus.
基因ID 8740
蛋白编号 O43557
预测分子量 19 kDa
SDS-PAGE 20-22 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

Tumor necrosis factor superfamily member 14 (TNFSF14), LIGHT, is a component of the cytokine network that regulates innate and adaptive immune responses, which promote homeostasis of lymphoid organs, liver, and bone. TNFSF14 is an immunomodulatory cytokine and a member of the TNF superfamily. It is expressed by lymphocytes, monocytes, and granulocytes, and is primarily known for its critical role in immune functions. TNFSF14 leads to T cell activation through interaction with HVEM by enhancing T cell proliferation and induces cytokine secretion through binding to lymphotoxin β receptor (LTβR) on mast cells. TNFSF14 has also been implicated in various pathogenic conditions related to inflammatory responses such as tumors, type 2 diabetes, and atherosclerosis.

参考文献:

1.Giacomina Brunetti. et al. (2020). J Bone Miner Res. 35(4):671-680 2.Marcos W Steinberg. et al. (2011). Immunol Rev. 244(1):169-187. 3.K Tamada. et al. (2000). J Immunol. 164(8):4105-4110. 4.Peter Stopfer. et al. (2004). J Immunol. 172(12):7459-7465. 5.W H Lee. et al. (2001). Arterioscler Thromb Vasc Biol. 21(12):2004-2010.